Rozemarijn S van Rijn Selected Research

Immune Checkpoint Inhibitors

1/2024	A prediction model for response to immune checkpoint inhibition in advanced melanoma.
5/2023	A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors.
1/2023	Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma.
10/2022	End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort Study.
9/2022	BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma.
9/2021	Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study.
4/2021	Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients.
1/2021	Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort Study.
1/2021	Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry.
1/2020	Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rozemarijn S van Rijn Research Topics

Disease

25	Melanoma (Melanoma, Malignant) 01/2024 - 01/2017
7	Neoplasms (Cancer) 01/2023 - 07/2006
5	Neoplasm Metastasis (Metastasis) 01/2024 - 06/2018
5	Brain Neoplasms (Brain Tumor) 05/2023 - 01/2018
2	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2007 - 09/2006
1	Death (Near-Death Experience) 10/2022
1	Hepatitis 04/2021
1	Immune System Diseases (Immune Disorders) 01/2021
1	Autoimmune Diseases (Autoimmune Disease) 01/2021
1	Necrosis 06/2018
1	B-Cell Lymphoma (Lymphoma, B Cell) 06/2018
1	Hodgkin Disease (Hodgkin's Disease) 06/2018
1	Colitis 01/2018
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2018
1	Leukemia 09/2006
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 07/2006

Drug/Important Bio-Agent (IBA)

11	Immune Checkpoint InhibitorsIBA 01/2024 - 12/2019
9	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2024 - 01/2018
7	IpilimumabIBA 01/2023 - 01/2018
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2024 - 12/2022
3	NivolumabIBA 01/2023 - 09/2022
2	Rituximab (Mabthera)FDA Link 01/2018 - 07/2006
1	A-factor (Streptomyces)IBA 09/2022
1	antineoplaston A10 (A 10)IBA 09/2021
1	Programmed Cell Death 1 ReceptorIBA 04/2021
1	Lactate DehydrogenasesIBA 11/2020
1	SteroidsIBA 01/2020
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 06/2018
1	VemurafenibIBA 01/2018
1	Monoclonal AntibodiesIBA 01/2018
1	Proteins (Proteins, Gene)FDA Link 01/2017
1	Phosphotransferases (Kinase)IBA 01/2017
1	MitogensIBA 01/2017
1	AntigensIBA 01/2007
1	AntibodiesIBA 07/2006

Therapy/Procedure

16	Therapeutics 01/2024 - 01/2018
1	Duration of Therapy 01/2022
1	Immunotherapy 05/2020
1	Drug Therapy (Chemotherapy) 01/2018
1	Stem Cell Transplantation 09/2006